Abstract
Purpose:This study was conducted to determine whether glucocorticoid supplementation for patients with polycystic ovarian disease during ovulation induction with gonadotropins for in vitro fertilization (IVF) therapy is beneficial.
Methods:Seventy-one cycles of patients undergoing first attempts at IVF, with classical polycystic ovarian disease and hyperandrogenemia, who enrolled in the IVF–embryo transfer program, were evaluated retrospectively. In 20 cycles (20 patients) glucocorticoid supplementation was noted and compared to 51 cycles (51 patients) without glucocorticoid as adrenal androgen suppression. Ovaries were stimulated by gonadotropin releasing hormone agonist, human menopausal gonadotropin, and dexamethasone. Ovarian responsiveness and IVF–embryo transfer outcome were analyzed and included the number of follicles >17 mm in diameter, serum estradiol concentration on the day of human chorionic gonadotropin administration, number of human chorionic gonadotropin ampoules administered, number of oocytes retrieved, percentage of oocytes fertilized, number of embryos transferred, implantation rate, and number of clinical pregnancies and their outcome.
Results:The results showed that the pregnancy rate in patients who received glucocorticoid was 22.1%, compared to 26% in the controls (statistically insignificant). The IVF cycle variables studied revealed no statistically significant differences.
Conclusions:Our observations did not support the notion that adrenal androgen suppression by glucocorticoid, or as an adjuvant therapy, is beneficial to patients with polycystic ovarian disease who enrolled in an IVF–embryo transfer program.
Keywords: glucocorticoid, IVF, ovulation induction, PCOD
Full Text
The Full Text of this article is available as a PDF (271.4 KB).
REFERENCES
- 1.Willman SP, Nass TE, Chetkowski RJ: A randomized trial of adrenal suppression for in vitro fertilization (IVF). Pacific Coast Fertil Soc Meet 1992;A23
- 2.Rein MS, Jackson KV, Sable DB, Thomas PP, Hornstein MD. Dexamethasone during ovulation induction for in-vitro fertilization: A pilot study. Hum Reprod. 1996;11:253–255. [PubMed] [Google Scholar]
- 3.Cedars MI, Steingold KA, de Ziegler D, Lapolt PS, Chang RJ, Judd HL. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: Assessment of the adrenal role in ovarian dysfunction. Feril Steril. 1992;57:495–500. doi: 10.1016/s0015-0282(16)54890-0. [DOI] [PubMed] [Google Scholar]
- 4.Lobo RA, Wellington P, March CM, Granger L, Keltzky OA. Clomiphene and dexamethasone in women unresponsive to clomiphene alone. Obstet Gynecol. 1982;60:497–501. [PubMed] [Google Scholar]
- 5.Evron S, Navot D, Laufer N, Diamant YZ. Induction of ovulation with combined human gonadotropins and dexamethasone in women with polycystic ovarian disease. Fertil Steril. 1983;40:183–186. doi: 10.1016/s0015-0282(16)47234-1. [DOI] [PubMed] [Google Scholar]
- 6.Daly DC, Walters CA, Soto-Albors CE, Tohan N, Riddick DH. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril. 1984;41:844–848. doi: 10.1016/s0015-0282(16)47896-9. [DOI] [PubMed] [Google Scholar]
- 7.Haning RVJ. Role of dehydroepiandrosterone sulphate as a prehormone for ovarian steroidogenesis. Obstet Gynecol. 1985;65:199–205. [PubMed] [Google Scholar]
- 8.Kemeter P, Feichtinger W. Prednisolone improves the pregnancy rate of IVF. A prospective randomized study. Fertilat. 1986;2:71–76. [Google Scholar]
- 9.Petermann TS, Rabenbauer B, Wildt L. The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women. Hum Reprod. 1993;8:1807–1812. doi: 10.1093/oxfordjournals.humrep.a137938. [DOI] [PubMed] [Google Scholar]
- 10.Kirschner MA, Jacobs JB. Combined ovarian and adrenal vein catheterization to determine the site of androgen over-production in hirsute women. J Clin Endocrinol Metab. 1971;33:199–209. doi: 10.1210/jcem-33-2-199. [DOI] [PubMed] [Google Scholar]
- 11.Stahl NL, Teeslink CR, Greenblatt RB. Ovarian, adrenal and peripheral testosterone levels in the polycystic ovary syndrome. Am J Obstet Gynecol. 1973;117:194–200. doi: 10.1016/0002-9378(73)90632-7. [DOI] [PubMed] [Google Scholar]
- 12.Hsueh AJW, Erickson GF. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids. 1978;32:639–648. doi: 10.1016/0039-128x(78)90074-0. [DOI] [PubMed] [Google Scholar]
- 13.Ben-Rafael Z, Benadiva CA, Garcia CJ, Flickinger GL. Cortisol stimulation of estradiol and progesterone secretion by human granulosa cells is independent of follicle-stimulating hormone effects. Fertil Steril. 1988;49:813–816. [PubMed] [Google Scholar]
- 14.Fateh M, Ben-Rafael Z, Benadiva C, Mastroianni L, Jr, Flickinger GL. Cortisol levels in human follicular fluid. Fertil Steril. 1989;51:538–541. doi: 10.1016/s0015-0282(16)60572-1. [DOI] [PubMed] [Google Scholar]
- 15.Bider D, Levran D, Mashiach S, Ben-Shlomo I, Dor J. Polycystic ovarian disease (PCOD)—Pregnancy rate and outcome in in vitro fertilization. J Assist Reprod Genet. 1993;10:11–14. doi: 10.1007/BF01204434. [DOI] [PubMed] [Google Scholar]
- 16.Bider D, Amoday I, Yonesh M, Yemini Z, Mashiach S., Dor J. Glucocorticoid administration during transfer of frozen-thawed embryos: A prospective, randomized study. Fertil Steril. 1996;66:154–156. doi: 10.1016/s0015-0282(16)58405-2. [DOI] [PubMed] [Google Scholar]